NAL 0.00% 0.6¢ norwood abbey limited

A lot of competition in the needle-free market. But this isn't...

  1. 1,165 Posts.
    A lot of competition in the needle-free market. But this isn't about needle-free technology, it's about being able to measure depth of patient skin/fat so as to get the drug into the right depth. Maybe that has a market somewhere. No idea. The company has been a shocker since 2004.
 
watchlist Created with Sketch. Add NAL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.